
éåã¯ç¡ç äžè¶³ã«ããå¿èç ãšæ»äº¡ãªã¹ã¯ãçžæ®ºã§ãããUKãã€ãªãã³ã¯ç ç©¶ãæããã«
éåã¯ç¡ç äžè¶³ã«ããå¿èç ãšæ»äº¡ãªã¹ã¯ãçžæ®ºã§ãããUKãã€ãªãã³ã¯ç ç©¶ãæããã« ç¡ç ãå°ãªãããããŸãã¯å€ãããããšã¯ãå¿è¡ç®¡çŸæ£ãæ©ææ»äº¡ã®ãªã¹ã¯äžæãšé¢é£ããŠããããèº«äœæŽ»åãç¶æããããšã§ãã®å±éºã®å€ããäžåã§ããå¯èœæ§ãããããšããæ°ããªãšããã³ã¹ã«ãã£ãŠç€ºåãããŠãããNutrition, Metabolism and Cardiovascular Diseasesã«æ²èŒãããå€§èŠæš¡çžŠæç ç©¶ã¯ãç¡ç äžè¶³ãšäœãèº«äœæŽ»åã®çµã¿åãããçžä¹çãªå¥åº·è¢«å®³ãçã¿åºãäžæ¹ãããé«ã掻åã¬ãã«ããªã¹ã¯ãç·©åããããã¯é転ãããããšãã§ããããšãæããã«ããã å京倧åŠå»åŠéšãšå京倧åŠã®Yiwen Daiãäž»å°ãããã®ç ç©¶ã¯ãUKãã€ãªãã³ã¯ã®87,879人ã®åå è ã®å é床èšããŒã¿ãçšããŠãç¡ç æéãšèº«äœæŽ»åãã©ã®ããã«çžäºäœçšããŠé·æçãªå¥åº·çµæã圢æãããã調æ»ãããèªå·±å ±åã«ããç¡ç ã«äŸåããåŸæ¥ã®ç ç©¶ã®ã»ãšãã©ãšã¯ç°ãªãããã®èª¿æ»ã§ã¯æéŠã«è£ çããæŽ»åãã©ãã«ãŒãçšããŠç¡ç ãšéåã®äž¡æ¹ã客芳çã«æž¬å®ããçŸå®äžçã®è¡åã®ããæ£ç¢ºãªåãæäŸããŠããã ç ç©¶çµæ åå è ã¯å é床èšã®æž¬å®å€ã«åºã¥ããŠ3ã€ã®ç¡ç ã«ããŽãªãŒã«åé¡ãããïŒäžååïŒ1æ©7æéæªæºïŒãæé©ïŒ7æé以äž10æéæªæºïŒãé·æéïŒ10æé以äžïŒãèº«äœæŽ»åã¯ã掻çºãªæ©è¡ãã©ã³ãã³ã°ããµã€ã¯ãªã³ã°ãªã©ã®äžçšåºŠããé«åŒ·åºŠã®èº«äœæŽ»åïŒMVPAïŒãšãæ£æ©ãå®¶äºãªã©ã®è»œåºŠã®èº«äœæŽ»åïŒLPAïŒãšããŠæž¬å®ãããã çµæã¯ãå¿è¡ç®¡çŸæ£ã®çºçãšå šæ»äº¡ã®äž¡æ¹ã«ãããŠãç¡ç ãšæŽ»åã®éã«æç¢ºãªçžå ççžäºäœçšã瀺ãããæãæªãçµæã¯ãç¡ç ãæªãã»ãšãã©åããªãã£ã人ã ã«éäžããŠããã äœMVPAã®åå è ã®ãã¡ã1æ©ã«10æé以äžç¡ç ããšã£ã人ã¯ãæé©ãªç¡ç æéã®äººãšæ¯èŒããŠå¿è¡ç®¡çŸæ£ãçºçãããªã¹ã¯ã17ïŒ é«ãã£ãïŒHR 1.17ã95ïŒ CI 1.01ã1.36ïŒãæ»äº¡çãªã¹ã¯ã¯ããã«é¡èã ã£ããäœMVPAãšç¡ç äžè¶³ã®çµã¿åããã¯å šæ»äº¡ãªã¹ã¯ã51ïŒ äžæããïŒHR 1.51ã95ïŒ CI 1.21ã1.89ïŒãäœMVPAãšé·æéç¡ç ã®çµã¿åããã¯20ïŒ äžæãããïŒHR 1.20ã95ïŒ CI 1.05ã1.36ïŒã ããå°è±¡çãªçºèŠã¯ãåå è ãååã«éåããå Žåã«äœãèµ·ãã£ããã§ãããé«ãMVPAã¯ãç¡ç äžè¶³ã«ããå±éºã®å€ããçžæ®ºããããã«èŠãããé·æéç¡ç ã®äººã ã®ãã¡ãé«ãMVPAãæããŠãã人ã ã¯ãå¿è¡ç®¡çŸæ£ã®ãªã¹ã¯ã24ïŒ äœãïŒHR 0.76ã95ïŒ CI 0.60ã0.97ïŒããªã¹ã¯å åãä¿è·å åã«å€ããŠãããåæ§ã«ãç¡ç äžè¶³ãšé«ãMVPAã®çµã¿åããã¯41ïŒ äœãå šæ»äº¡ãªã¹ã¯ãšé¢é£ãïŒHR 0.59ã95ïŒ CI 0.40ã0.85ïŒãé·æéç¡ç ãšé«ãMVPAã¯30ïŒ ã®æžå°ã瀺ããïŒHR 0.70ã95ïŒ CI 0.56ã0.88ïŒã 軜床ã®èº«äœæŽ»åãåæ§ã®ä¿è·ãã¿ãŒã³ã瀺ããããäœåŒ·åºŠã®éåã§ãç¡ç æéãäžååãªäººã ã«ãšã£ãŠææçŸ©ãªãªã¹ã¯è»œæžãããããå¯èœæ§ã瀺åãããã éèŠæ§ å¿è¡ç®¡çŸæ£ã¯äžçäžã§æ»äº¡åå ã®ç¬¬1äœã§ãããç¡ç é害ã¯äººå£ã®çžåœéšåã«åœ±é¿ãäžããŠãããåŸæ¥ã®å ¬è¡è¡çã¡ãã»ãŒãžã¯ãç¡ç ãšéåãå¥ã ã®è¡åç®æšãšããŠæ±ã£ãŠããããã®ç ç©¶ã¯ãããããäžç·ã«åãçµãã¹ãã§ããããšã瀺åããŠããã çžä¹äœçšã¯åæ¹åã«åããç¡ç äžè¶³ã¯åº§ããã¡ãªçæŽ»ç¿æ £ã®å®³ãå¢å¹ ããäœã掻åã¯ç¡ç äžè¶³ã®å®³ãå¢å¹ ãããå®çšçãªæå³ã¯ãä»äºã®ã¹ã±ãžã¥ãŒã«ãå®¶åºã®çŸ©åããŸãã¯åºç€çãªå¥åº·ç¶æ ã®ããã«çæ³çãªç¡ç æéãéæã§ããªã人ã ã§ãã宿çãªèº«äœæŽ»åãéããŠå¿èã®å¥åº·ãå®ãããšãã§ããå¯èœæ§ããããšããããšã§ãããéã«ã掻åçã«éããããšãé£ãã人ã ã¯ãç¡ç äžè¶³ã®åœ±é¿ãåãããããªãå¯èœæ§ãããã èªå·±å ±åã§ã¯ãªãå é床èšã䜿çšããããšã¯ãéèŠãªåŒ·ã¿ã§ãããå€ãã®ç¡ç ç ç©¶ã¯åå è ãã©ãã ãç ã£ãããæãåºãããšã«äŸåããŠãããããã¯ä¿¡é Œæ§ãäœãããšã§ç¥ãããŠããã客芳çãªæž¬å®ã¯å®éã®ç¡ç æéãããæ£ç¢ºã«æãã芳å¯ç ç©¶ã®çµæãæªããå¯èœæ§ã®ãããã€ã¢ã¹ãäœæžããã éç 芳å¯ç ç©¶ãšããŠããããã®çºèŠã¯å æé¢ä¿ã§ã¯ãªãé¢é£æ§ã瀺ããŠãããé£äºã瀟äŒçµæžçå°äœã䜵åçŸæ£ãè·æ¥äžã®èŠæ±ãªã©ã®æªæž¬å®ã®äº€çµ¡å€æ°ããç¡ç ãšæŽ»åãã¿ãŒã³ã®äž¡æ¹ã«åœ±é¿ãäžããå¯èœæ§ããããUKãã€ãªãã³ã¯ã®ã³ããŒãã¯äžè¬ã®è±åœäººå£ãããå¥åº·ã§è£çŠã§ãããäžè¬åå¯èœæ§ãå¶éãããå¯èœæ§ããããããã«ãç¡ç ã®æçåãèŠéææ°ãæŠæ¥ãªãºã ãªã©ã®èŠå ãå«ããæé以å€ã®ç¡ç ã®è³ªã¯çŽæ¥è©äŸ¡ãããŠããããå¿è¡ç®¡ãªã¹ã¯ã«ç¬ç«ããŠåœ±é¿ãäžããå¯èœæ§ãããã çµè« ç¡ç äžè¶³ãšäœãèº«äœæŽ»åã¯çžä¹çã«çµã¿åããã£ãŠãå¿è¡ç®¡çŸæ£ã𿩿æ»äº¡ã®ãªã¹ã¯ãé«ãããããããç¹ã«äžçšåºŠããé«åŒ·åºŠã®éåãšãã£ãé«ãã¬ãã«ã®èº«äœæŽ»åã¯ããããã®ãªã¹ã¯ãææã«è»œæžããå Žåã«ãã£ãŠã¯é転ãããããã«èŠãããæé©ãªç¡ç æéãéæã§ããªã人ã ã«ãšã£ãŠãèº«äœæŽ»åãç¶æããããšã¯ãå¿èã®å¥åº·ãšé·å¯¿ãå®ãããã®åŒ·åãªä»£åæŠç¥ãšãªãå¯èœæ§ãããã åºå žïŒ Yiwen Dai, et al. ãJoint associations of accelerometer-measured sleep duration and physical activity with cardiovascular disease and all-cause mortality: a [âŠ]










